Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Guggenheim Remains a Buy on ProMIS Neurosciences (PMN)

Tipranks - Tipranks - Sat Feb 7, 6:58AM CST

In a report released yesterday, Eddie Hickman from Guggenheim maintained a Buy rating on ProMIS Neurosciences, with a price target of $35.00. The company’s shares closed yesterday at $13.10.

Claim 50% Off TipRanks Premium

According to TipRanks, Hickman is a 4-star analyst with an average return of 23.6% and a 68.97% success rate. Hickman covers the Healthcare sector, focusing on stocks such as ProMIS Neurosciences, Atai Beckley N.V., and Cybin.

ProMIS Neurosciences has an analyst consensus of Strong Buy, with a price target consensus of $29.33, a 123.89% upside from current levels. In a report released on January 30, TipRanks – Google also upgraded the stock to a Buy with a $13.50 price target.

See today’s best-performing stocks on TipRanks >>

Based on ProMIS Neurosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.58 million. In comparison, last year the company had a net profit of $9.28 million

Read More on PMN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).